Latest news
FDA Expands Approval of Pluvicto® for Metastatic Prostate Cancer: Targets a Protein Called PSMA - Memorial Sloan Kettering Cancer CenterMemorial Sloan Kettering Cancer Center · Thu, 06 Aug 2026 04:00:00 GMTCADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data - StocktwitsStocktwits · Wed, 05 Aug 2026 19:13:14 GMTCorrection to Novartis Wins FDA Approval for Expanded Prostate Cancer Treatment Article on July 31 - marketscreener.commarketscreener.com · Mon, 03 Aug 2026 21:53:12 GMTFDA expands Pluvicto label, making it available to most metastatic prostate cancer patients - Endpoints NewsEndpoints News · Mon, 03 Aug 2026 15:26:00 GMTFDA Expands Approval of Pluvicto in Combination with ARPI for PSMA-Positive mAPMN/S Prostate Cancer - diagnosticimaging.comdiagnosticimaging.com · Sat, 01 Aug 2026 13:16:50 GMTNovartis Wins FDA Approval for Expanded Prostate Cancer Treatment For Pluvicto - MoomooMoomoo · Fri, 31 Jul 2026 21:06:00 GMT